Black Diamond Therapeutics (BDTX) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free BDTX Stock Alerts $5.35 -0.09 (-1.65%) (As of 11:33 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:30 AM | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) Price Target Cut to $11.00HC Wainwright cut their price target on shares of Black Diamond Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday.May 15 at 3:22 AM | americanbankingnews.comShort Interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Grows By 13.6%May 13 at 5:41 AM | americanbankingnews.comWedbush Weighs in on Black Diamond Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:BDTX)May 13 at 1:20 AM | americanbankingnews.comComparing Black Diamond Therapeutics (NASDAQ:BDTX) and Exscientia (NASDAQ:EXAI)May 10, 2024 | msn.comShould You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?May 9, 2024 | sfgate.comBlack Diamond: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comBlack Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 28, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest UpdateBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,760,000 shares, a decrease of 13.7% from the March 31st total of 2,040,000 shares. Based on an average daily trading volume, of 629,900 shares, the short-interest ratio is currently 2.8 days.April 24, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 14, 2024 | marketbeat.comShort Interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Expands By 12.7%Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,040,000 shares, a growth of 12.7% from the March 15th total of 1,810,000 shares. Based on an average trading volume of 592,500 shares, the short-interest ratio is currently 3.4 days.April 11, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Changes to Board of DirectorsApril 11, 2024 | marketbeat.comBrokers Set Expectations for Black Diamond Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Analysts at Wedbush issued their Q1 2024 EPS estimates for Black Diamond Therapeutics in a research report issued on Monday, April 8th. Wedbush analyst R. Driscoll anticipates that the company will post earnings of ($0.41) per share fApril 8, 2024 | finance.yahoo.comWall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should KnowApril 8, 2024 | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) Price Target Raised to $16.00 at WedbushWedbush lifted their target price on shares of Black Diamond Therapeutics from $10.00 to $16.00 and gave the stock an "outperform" rating in a research note on Monday.April 7, 2024 | globenewswire.comBlack Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual MeetingApril 3, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesMarch 20, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Black Diamond Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of Black Diamond Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will post eMarch 18, 2024 | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $12.00 price objective (up previously from $11.00) on shares of Black Diamond Therapeutics in a report on Monday.March 18, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. Forecasted to Earn FY2024 Earnings of ($1.76) Per Share (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush increased their FY2024 earnings estimates for Black Diamond Therapeutics in a research report issued on Wednesday, March 13th. Wedbush analyst R. Driscoll now expects that the company will earn ($1.76)March 18, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decline in Short InterestBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decrease in short interest in the month of February. As of February 29th, there was short interest totalling 1,780,000 shares, a decrease of 5.3% from the February 14th total of 1,880,000 shares. Based on an average daily volume of 577,500 shares, the days-to-cover ratio is currently 3.1 days.March 14, 2024 | finance.yahoo.comBlack Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...March 13, 2024 | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Reaffirmed by WedbushWedbush restated an "outperform" rating and set a $10.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday.March 12, 2024 | globenewswire.comBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 5, 2024 | globenewswire.comBlack Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024March 2, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Drop in Short InterestBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 1,880,000 shares, a decrease of 21.7% from the January 31st total of 2,400,000 shares. Based on an average daily volume of 537,500 shares, the days-to-cover ratio is currently 3.5 days.February 29, 2024 | seekingalpha.comBDTX Black Diamond Therapeutics, Inc.February 28, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 21, 2024 | marketbeat.comBarclays PLC Acquires 197,895 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Barclays PLC lifted its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 159.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 322,246 shares of the company's stock after purchasing an addFebruary 16, 2024 | uk.investing.comBlack Diamond Therapeutics Inc (BDTX)February 13, 2024 | marketbeat.comBlack Diamond Therapeutics (NASDAQ:BDTX) Trading Up 2.6%Black Diamond Therapeutics (NASDAQ:BDTX) Trading 2.6% HigherJanuary 24, 2024 | wsj.comBlack Diamond Therapeutics Inc.January 4, 2024 | finance.yahoo.comBlack Diamond Therapeutics Announces Corporate Update and Expected 2024 MilestonesJanuary 3, 2024 | marketbeat.comShort Interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increases By 6.4%Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,640,000 shares, a growth of 6.4% from the November 30th total of 3,420,000 shares. Based on an average daily volume of 522,100 shares, the days-to-cover ratio is currently 7.0 days.December 14, 2023 | msn.comBlack Diamond reports positive topline data for GBM drugDecember 14, 2023 | markets.businessinsider.comBuy Rating Reaffirmed for Black Diamond Therapeutics Amid Promising BDTX-1535 Trial Results and Strategic DevelopmentDecember 13, 2023 | finance.yahoo.comBlack Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBMDecember 5, 2023 | finance.yahoo.comWith 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backingNovember 9, 2023 | washingtonpost.comSolitario: Q3 Earnings SnapshotNovember 6, 2023 | finance.yahoo.comBlack Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comBlack Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate UpdateOctober 31, 2023 | morningstar.comBlack Diamond Therapeutics Inc Ordinary Shares BDTXOctober 17, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Ultragenyx Pharmaceutical (RARE)October 16, 2023 | markets.businessinsider.comBlack Diamond Therapeutics (BDTX) Receives a Buy from Piper SandlerOctober 14, 2023 | finance.yahoo.comBlack Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535October 12, 2023 | msn.comBlack Diamond's BDTX-1535: A Brainy Bet In Cancer TherapyOctober 4, 2023 | finance.yahoo.comBlack Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 18, 2023 | finance.yahoo.comCo-founder of cancer biotech Black Diamond replaced as CEOSeptember 18, 2023 | marketwatch.comBlack Diamond Therapeutics Chairman to Succeed Departing CEOSeptember 18, 2023 | finance.yahoo.comBlack Diamond Therapeutics Announces CEO TransitionSeptember 12, 2023 | msn.comWedbush Reiterates Black Diamond Therapeutics (BDTX) Outperform Recommendation Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. BDTX Media Mentions By Week BDTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDTX News Sentiment▼1.070.55▲Average Medical News Sentiment BDTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDTX Articles This Week▼121▲BDTX Articles Average Week Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AURA News Today TNYA News Today SLDB News Today OCGN News Today TRML News Today MGTX News Today JSPR News Today TCRX News Today CRBU News Today REPL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCharles Payne Demystifies OptionsUnstoppable ProsperityTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
